humodar c25 100r 100 ui/ml suspensie injectabilă
indar sap pentru producerea insulinelor - insulinum umane - suspensie injectabilă - 100 ui/ml
humodar r 100r 100 ui/ml soluţie injectabilă
indar sap pentru producerea insulinelor - insulinum umane - soluţie injectabilă - 100 ui/ml
wilate 500 500 ui/500 ui pulbere şi solvent pentru soluţie injectabilă
octapharma pharmazeutika produktionsges. m.b.h - factorul viii de coagulare uman/factor von willebrand - pulbere şi solvent pentru soluţie injectabilă - 500 ui/500 ui
wilate 1000 1000 ui/1000 ui pulbere şi solvent pentru soluţie injectabilă
octapharma pharmazeutika produktionsges. m.b.h - factorul viii de coagulare uman/factor von willebrand - pulbere şi solvent pentru soluţie injectabilă - 1000 ui/1000 ui
septanest 40 mg ml with adrenaline 1 100 000 68 mg/17 mcg soluţie injectabilă
septodont sas - articainum + epinephrinum - soluţie injectabilă - 68 mg/17 mcg
humodar r 100r 100 ui/ml soluţie injectabilă
sap „indar” - insulinum umane - soluţie injectabilă - 100 ui/ml
humodar c25 100r 100 ui/ml suspensie injectabilă
sap „indar” - insulinum umane - suspensie injectabilă - 100 ui/ml
humodar b 100r 100 ui/ml suspensie injectabilă
sap „indar” - insulinum umane - suspensie injectabilă - 100 ui/ml
cefazolin sandoz pulbere pentru solutie injectabila 1 g
sandoz pharmaceuticals d.d. - cefazolinum - pulbere pentru solutie injectabila - 1 g
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.